title: Activating and resistance mutations of EGFR in non-small-cell lung cancer: role in clinical response to EGFR tyrosine kinase inhibitors.
abstract: The epidermal growth factor receptor tyrosine kinase inhibitors (EGFR TKIs), gefitinib and erlotinib, are reversible competitive inhibitors of the tyrosine kinase domain of EGFR that bind to its adenosine-5' triphosphate-binding site. Somatic activating mutations of the EGFR gene, increased gene copy number and certain clinical and pathological features have been associated with dramatic tumor responses and favorable clinical outcomes with these agents in patients with non-small-cell lung cancer (NSCLC). The specific types of activating mutations that confer sensitivity to EGFR TKIs are present in the tyrosine kinase (TK) domain of the EGFR gene. Exon 19 deletion mutations and the single-point substitution mutation L858R in exon 21 are the most frequent in NSCLC and are termed 'classical' mutations. The NSCLC tumors insensitive to EGFR TKIs include those driven by the KRAS and MET oncogenes. Most patients who initially respond to gefitinib and erlotinib eventually become resistant and experience progressive disease. The point mutation T790M accounts for about one half of these cases of acquired resistance. Various second-generation EGFR TKIs are currently being evaluated and may have the potential to overcome T790M-mediated resistance by virtue of their irreversible inhibition of the receptor TK domain.
authors.affiliation: Hamon Center for Therapeutic Oncology Research and Department of Pathology, University of Texas Southwestern Medical Center, Dallas, Texas 75390, USA. adi.gazdar@utsouthwestern.edu
authors.forename: A F
authors.initials: AF
authors.lastname: Gazdar
mesh_terms: D002289:Carcinoma, Non-Small-Cell Lung / Q000188:drug therapy* / Q000235:genetics; D019008:Drug Resistance, Neoplasm / Q000235:genetics*; D066246:ErbB Receptors / Q000037:antagonists & inhibitors / Q000235:genetics*; D000069347:Erlotinib Hydrochloride; D000077156:Gefitinib; D005784:Gene Amplification; D006801:Humans; D008175:Lung Neoplasms / Q000188:drug therapy* / Q000235:genetics; D017354:Point Mutation; D047428:Protein Kinase Inhibitors / Q000627:therapeutic use*; D017434:Protein Structure, Tertiary / Q000187:drug effects; D011518:Proto-Oncogene Proteins / Q000235:genetics; D019859:Proto-Oncogene Proteins c-met; D016283:Proto-Oncogene Proteins p21(ras); D011799:Quinazolines / Q000627:therapeutic use; D017978:Receptors, Growth Factor / Q000235:genetics; D017384:Sequence Deletion; D016896:Treatment Outcome; D018631:ras Proteins / Q000235:genetics
chemical_list: C117307:KRAS protein, human; D047428:Protein Kinase Inhibitors; D011518:Proto-Oncogene Proteins; D011799:Quinazolines; D017978:Receptors, Growth Factor; D000069347:Erlotinib Hydrochloride; C512478:EGFR protein, human; D066246:ErbB Receptors; C491743:MET protein, human; D019859:Proto-Oncogene Proteins c-met; D016283:Proto-Oncogene Proteins p21(ras); D018631:ras Proteins; D000077156:Gefitinib
references.citation: JAMA. 2003 Oct 22;290(16):2149-58
references.pmid: 14570950
references.citation: PLoS Med. 2005 Nov;2(11):e313
references.pmid: 16187797
references.citation: Cell. 2006 Jun 16;125(6):1137-49
references.pmid: 16777603
references.citation: Clin Cancer Res. 2009 Mar 15;15(6):2076-84
references.pmid: 19276259
references.citation: Clin Cancer Res. 2007 Aug 1;13(15 Pt 2):s4593-6
references.pmid: 17671147
references.citation: J Clin Oncol. 2005 Apr 10;23(11):2513-20
references.pmid: 15738541
references.citation: Ann Oncol. 2005 Jul;16(7):1081-6
references.pmid: 15851406
references.citation: J Clin Oncol. 2008 Apr 1;26(10):1742-51
references.pmid: 18375904
references.citation: Cancer Res. 2004 Dec 15;64(24):8919-23
references.pmid: 15604253
references.citation: Ann Thorac Surg. 2008 Apr;85(4):1430-2
references.pmid: 18355544
references.citation: Genes Dev. 2006 Jun 1;20(11):1496-510
references.pmid: 16705038
references.citation: N Engl J Med. 2005 Jul 14;353(2):123-32
references.pmid: 16014882
references.citation: Proc Natl Acad Sci U S A. 2008 Feb 12;105(6):2070-5
references.pmid: 18227510
references.citation: J Clin Oncol. 2005 Apr 10;23(11):2493-501
references.pmid: 15710947
references.citation: Clin Cancer Res. 2006 Feb 1;12(3 Pt 1):839-44
references.pmid: 16467097
references.citation: Cancer Res. 2006 Aug 15;66(16):8163-71
references.pmid: 16912195
references.citation: Clin Cancer Res. 2006 Jul 1;12(13):3908-14
references.pmid: 16818686
references.citation: Cancer Res. 2005 Oct 1;65(19):8968-74
references.pmid: 16204070
references.citation: J Clin Oncol. 2005 Sep 1;23(25):5900-9
references.pmid: 16043828
references.citation: J Clin Oncol. 2008 Jun 1;26(16):2745-53
references.pmid: 18509184
references.citation: Clin Cancer Res. 2006 Oct 1;12(19):5764-9
references.pmid: 17020982
references.citation: Cancer Prev Res (Phila). 2008 Aug;1(3):156-60
references.pmid: 19138950
references.citation: J Clin Oncol. 2006 Mar 1;24(7):1219-20; author reply 1220-1
references.pmid: 16505443
references.citation: N Engl J Med. 2008 Mar 13;358(11):1160-74
references.pmid: 18337605
references.citation: PLoS Med. 2005 Nov;2(11):e377
references.pmid: 16288556
references.citation: J Clin Oncol. 2003 Jun 15;21(12):2237-46
references.pmid: 12748244
references.citation: J Clin Oncol. 2005 Oct 1;23(28):6829-37
references.pmid: 15998907
references.citation: Proc Natl Acad Sci U S A. 2004 Sep 7;101(36):13306-11
references.pmid: 15329413
references.citation: Clin Cancer Res. 2006 Jul 15;12(14 Pt 2):4416s-4420s
references.pmid: 16857820
references.citation: Clin Cancer Res. 2009 Jan 15;15(2):460-7
references.pmid: 19147750
references.citation: PLoS Med. 2005 Jan;2(1):e17
references.pmid: 15696205
references.citation: Nat Rev Cancer. 2007 Mar;7(3):169-81
references.pmid: 17318210
references.citation: J Clin Oncol. 2004 Mar 15;22(6):1103-9
references.pmid: 15020612
references.citation: Endocr Relat Cancer. 2005 Jul;12 Suppl 1:S17-27
references.pmid: 16113093
references.citation: N Engl J Med. 2005 Feb 24;352(8):786-92
references.pmid: 15728811
references.citation: Cancer Res. 2007 Dec 15;67(24):11924-32
references.pmid: 18089823
references.citation: Clin Cancer Res. 2007 Aug 1;13(15 Pt 2):s4606-12
references.pmid: 17671150
references.citation: Lancet. 2005 Oct 29-Nov 4;366(9496):1527-37
references.pmid: 16257339
references.citation: Oncogene. 2008 Aug 7;27(34):4702-11
references.pmid: 18408761
references.citation: Br J Cancer. 2008 Mar 11;98(5):923-30
references.pmid: 18319715
references.citation: Science. 2004 Jun 4;304(5676):1497-500
references.pmid: 15118125
references.citation: Clin Cancer Res. 2006 Nov 1;12(21):6494-501
references.pmid: 17085664
references.citation: Int J Cancer. 2006 Jan 15;118(2):257-62
references.pmid: 16231326
references.citation: J Clin Oncol. 2004 Aug 15;22(16):3238-47
references.pmid: 15310767
references.citation: N Engl J Med. 2008 Jul 24;359(4):366-77
references.pmid: 18596266
references.citation: PLoS Med. 2005 Mar;2(3):e73
references.pmid: 15737014
references.citation: N Engl J Med. 2004 May 20;350(21):2129-39
references.pmid: 15118073
references.citation: Proc Natl Acad Sci U S A. 2005 May 24;102(21):7665-70
references.pmid: 15897464
references.citation: J Natl Cancer Inst. 2005 May 4;97(9):643-55
references.pmid: 15870435